The Purvalanol A (CDK Inhibitor) market has demonstrated impressive growth, expanding from $0.64 billion in 2025 to $0.7 ...

Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Kailera Therapeutics launched with a four-drug pipeline aimed at the ...

Roche’s Genentech subsidiary has agreed to pay the biotechnology firm Regor Pharmaceuticals $850 million, plus possible milestone payments, for a portfolio of CDK inhibitors for treating breast cancer ...

(RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced it has reached an agreement to acquire GT Apeiron’s share of its oral CDK7 inhibitor programme, gaining full control of ...